Patent intelligence · US
US 11339150
Benzimidazole compounds as HDAC6 inhibitors
Benzimidazole compounds as HDAC6 inhibitors
Patent details — US 11339150
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 24, 2022
- Expiration
- May 19, 2042
- Applicant
- OnKure, Inc.
- Claims
- 23
- CPC classes
- A61K, A61K45/06
Quick answer
US 11339150 (Benzimidazole compounds as HDAC6 inhibitors) is held by OnKure, Inc.. Status: granted. Granted May 24, 2022. Expires May 19, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- OnKure, Inc.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K45/06
More from OnKure, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12252511
Process for the preparation of cyclic depsipeptides
granted -
US 11739123
Process for the preparation of cyclic depsipeptides
granted -
US 11203602
Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
granted -
US 11053284
Process for the preparation of cyclic depsipeptides
granted -
US 10689419
Process for the preparation of cyclic depsipeptides
granted -
US 10100089
Process for the preparation of cyclic depsipeptides
granted
Frequently asked questions
What is US patent 11339150?
US 11339150 (Benzimidazole compounds as HDAC6 inhibitors) is held by OnKure, Inc.. Status: granted. Granted May 24, 2022. Expires May 19, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11339150?
OnKure, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11339150 expire?
Our index shows an expiration date of May 19, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.